We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 01, 2020

Nab-Paclitaxel in Older Patients With NSCLC With Disease Progression After Platinum-Based Doublet Chemotherapy

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
Nab-Paclitaxel in Older Patients With Non-Small Cell Lung Cancer Who Have Developed Disease Progression After Platinum-Based Doublet Chemotherapy
Cancer 2020 Jan 14;[EPub Ahead of Print], JM Weiss, N Pennell, AM Deal, D Morgenzstern, DS Bradford, J Crane, HJ West, C Lee, C Pecot, JP Stevenson, W Irvin, M Socinski, T Stinchcombe, LC Villaruz, HB Muss

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading